Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors

Clinica Chimica Acta

Volumn 360, Issue 1-2, 2005, Pages 187-193

  Hess, Georg ^a   Runkel, Stefan ^b   Zdunek, Dietmar ^a   Hitzler, Walter E ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cardiac function; Creatinine clearance; Glomerular filtration rate (GFR); Hemoglobin (Hb); N terminal pro B type natriuretic peptide (NT proBNP); Natriuretic peptides (NP)

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD DONOR; CHEMOLUMINESCENCE; CLUSTER ANALYSIS; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); FEMALE; GENDER; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOASSAY; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BLOOD DONORS; CREATININE; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOASSAY; LUMINESCENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REFERENCE VALUES; SEX FACTORS;

EID: 24044506292     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2005.04.031     Document Type: Article

References (21)

1. J.A. Sundsfjord, G. Thibault, P. Larochelle, and M. Cantin Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man J Clin Endocrinol Metab 66 3 1988 605 610
2. N.C. Davidson, A.A. Naas, J.K. Hanson, N.S. Kennedy, W.J. Coutie, and A.D. Struthers Comparison of atrial natriuretic peptide, b-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction Am J Cardiol 77 1996 828 831
3. V. Raizada, K. Thakore, W. Luo, and P.G. McGuire Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension Mol Cell Biochem 216 1-2 2001 137 140
4. E.R. Levin, D.G. Gardner, and W.K. Samson Natriuretic peptides N Engl J Med 339 1998 321 328
5. C. Hall Essential biochemistry and physiology of (NT-pro) BNP Eur J Heart Fail 6 2004 257 260
6. J. Yeo, A. Wu, and F. Apple A multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay Clin Chim Acta 338 2003 107 115
7. S.C. Barnes, P.O. Collinson, G. Galasko, A. Lahiri, and R. Senior Evaluation of N-terminal pro-B type natriuretic Peptide analysis on the Elecsys 1010 and 2010 analysers Ann Clin Biochem 41 2004 459 463
8. M.T. Rademaker, and A.M. Richards Cardiac natriuretic peptides for cardiac health Clin Sci 108 2005 23 26
9. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Bundesgesundheitsbl- Gesundheitsforsch-Gesundheitsschutz 43 (2000) 555-589.
10. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. K. Erler ELECSYS® immunoassay systems using electrochemiluminescence detection Wien Klin Wochenschr 12 1998 5 10
12. I. Loke, I.B. Squire, J.E. Davies, and L.L. Ng Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate Eur J Heart Fail 5 5 2003 599 606
13. I. Raymond, B.A. Groenning, and P.R. Hildebrandt The influence of age, sex and other variables on the plasma level of N-terminal pro-brain natriuretic peptide in a large sample of the general population Heart 89 2003 745 751
14. D.S. Silverberg, D. Wexler, and I. Adrian The importance of anaemia and its correction in the management of severe congestive heart failure Eur J Heart Fail 4 2002 681e 686e
15. I. Anand, J. McMurray, J. Whitmore, M. Warren, M.A. McCamish, and P. Burton Anemia and its relationship to clinical outcome in heart failure Circulation 110 2004 149 154
16. J. Coresh, B.C. Astor, T. Greene, G. Eknoyan, and A.S. Levey Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey Am J Kidney Dis 41 2003 1 12
17. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2169
18. W.M. McClellan, R.D. Langston, and R. Presley Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease J Am Soc Nephrol 15 2004 1912 1919
19. C. Kragelund, B. Groenning, L. Kober, P. Hildebrandt, and R. Steffensen N-terminal ProB-Type natriuretic peptide and long-term mortality in stable coronary heart disease New Engl J Med 352 2005 666 675
20. L. Tarnow, P. Hildebrandt, B.V. Hansen, K. Borch-Johnson, and H.H. Parving Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy Diabetologia 48 2005 149 155
21. P. Gaede, P. Hildebrandt, G. Hess, H.H. Parving, and O. Pedersen Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria Diabetologia 48 2005 156 163